Biogen is officially pivoting away from Aduhelm, the first Alzheimer's treatment the Cambridge drugmaker made in collaboration with Japanese pharma Eisai Inc., and focusing its resources on recently-approved Leqembi and other potential new Alzheimer's treatments.
One year ago, Biogen said it began a strategic review of its research and development efforts. At the time, the company was bleeding cash and said it was looking at ways to cut costs.
STAY IN THE KNOW
 |
Watch NBC10 Boston news for free, 24/7, wherever you are. |
 |
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters. |
Copyright Boston Business Journal
